Abstract

Hallopeau acrodermatitis (ACH) is a rare type of psoriasis that significantly affects patients’ quality of life. ACH has received insufficient attention compared to other forms of psoriasis. Given the chronic and relapsing nature and the debilitating complications of this disease, it is essential to thoroughly investigate its triggering factors and pathogenic mechanisms, and thus better understand the disease’s development and find new and more specific treatment targets. Diagnosing the disease can be challenging in the absence of plaque psoriasis lesions, which is why it is important for primary care physicians to be aware of the existence of ACH and to refer suspected patients to a dermatologist. Since topical treatment is often ineffective for Hallopeau acrodermatitis, patients may require systemic therapy to maintain their quality of life and ability to work. Although systemic treatment can be prescribed for ACH patients, similarly to those with plaque psoriasis, managing the disease is complex and requires patience from both patient and physician.